From Yahoo Finance: 2025-05-15 18:03:00

Biohaven faces a setback as the FDA delays the decision on its new drug by three months. The stock plummets almost 20%, contrasting the S&P 500’s 0.4% rise. Investors await the FDA’s review and potential advisory committee meeting for Biohaven’s promising treatment targeting a rare brain disorder.

Read more: Why Biohaven Stock Dove by Nearly 20% on Thursday